Clinical Trial: NCT01596751
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Hope Rugo, MD |
| Information Provided By: | University of California, San Francisco |
| Last Update Posted: | 2020-07-17 |
Study Overview
Brief Summary
The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397 when given in combination with standard dose eribulin (Halaven™). The purpose of the Phase 2 portion of the study is to find out what effects, good and/or bad, these drugs have on patients and their metastatic breast cancer.
Official Title
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Intervention / Treatment
- Drug: PLX3397
- Drug: Eribulin
Other Study ID Numbers
- 12751
- NCI-2015-01321
Start Date (Actual)
2012-07-12
Primary Completion Date (Actual)
2017-07-05
Study Completion Date (Actual)
2019-07-05
Enrollment (Actual)
67
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Hope Rugo, MD |
| Information Provided By: | University of California, San Francisco |
| Last Update Posted: | 2020-07-17 |
Study Overview
Brief Summary
The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397 when given in combination with standard dose eribulin (Halaven™). The purpose of the Phase 2 portion of the study is to find out what effects, good and/or bad, these drugs have on patients and their metastatic breast cancer.
Official Title
Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Intervention / Treatment
- Drug: PLX3397
- Drug: Eribulin
Other Study ID Numbers
- 12751
- NCI-2015-01321
Start Date (Actual)
2012-07-12
Primary Completion Date (Actual)
2017-07-05
Study Completion Date (Actual)
2019-07-05
Enrollment (Actual)
67
Study Type
Interventional
Phase
Phase 1, Phase 2